PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer

Qi Jiang, MM¹, Mixue Xie, MM², Mengye He, MM³, Feifei Yan, MM³, Ming Chen, MM³, Suzhen Xu, MM³, Xiaochen Zhang, MD³,⁴*, Peng Shen, MD³,⁴*

Abstract
Aims: Prostate cancer is one of the most common malignancies in men. Biochemical recurrence (BCR) and progression following curative treatment pose a significant public health challenge. Thus, it is essential to explore effective biomarkers for disease progression monitoring and risk stratification. The promoter region of the paired-like homeodomain transcription factor 2 (PITX2) gene has been found to be frequently methylated in prostate cancer. However, the prognostic role of PITX2 methylation in prostate cancer and which patients most likely are recommended for PITX2 methylation tests to assess BCR risk remain controversial. Therefore, a systematic review was performed to explore the relationship of PITX2 methylation with the BCR risk of prostate cancer.

Methods: The PubMed, EMBASE, and Cochrane Library databases were systematically searched for eligible studies. Seven studies with a total of 2185 patients were included. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated.

Results: The overall HR was 2.71 (95% CI, 2.21–3.31), suggesting that PITX2 methylation has an adverse impact on BCR of prostate cancer. The pooled estimate of 5-year BCR-free survival for patients with a high methylation status was significantly lower than that for patients with a low methylation status (71% vs 90%; odds ratio [OR] = 3.50; 95% CI, 2.67–4.60, P = .000). A subgroup analysis was conducted according to detection method: the combined HRs were 2.68 (95% CI, 2.02–3.55) for quantitative methylation-specific PCR (qMSP) and 3.29 (95% CI, 2.31–4.68) for microarray Epichip. In subgroups defined by region, Gleason score, pathological stage, surgical margin status and ethnicity, high methylation status was also associated with BCR of prostate cancer.

Conclusions: As an effective biomarker, PITX2 methylation is feasible for individualized BCR risk assessment of prostate cancer following radical prostatectomy.

Abbreviations: APC = adenomatous polyposis coli, BCR = biochemical recurrence, CIs = confidence intervals, GS = Gleason score, HRs = hazard ratios, PITX2 = paired-like homeodomain transcription factor 2, PSA = prostatic specific antigen, qMSP = quantitative methylation-specific PCR.

Keywords: biochemical recurrence, meta-analysis, methylation, PITX2, prostate cancer

1. Introduction
Prostate cancer imposes a great health burden on men, while its incidence has significantly increased in recent years. According to the latest estimates of global cancer incidence, prostate cancer is a third most common malignancy among men and the ranks sixth in the world.[1] Radical prostatectomy has been used as the main primary treatment for prostate cancer for many years with excellent oncologic results. However, recurrence of prostate cancer following radical prostatectomy is an important public health challenge. Up to 20% of patients develop biochemical recurrence (BCR) within 5 years of radical prostatectomy, and many subsequently develop metastatic diseases.[2] Prostatic specific antigen (PSA) has been the pivotal tool for recurrence diagnosis and is introduced as a BCR marker. A rising serum PSA level after achieving undetectable value is the first sign of recurrent disease and defined as BCR in year 2003.[3] Over time, it was possible to realize that PSA relapse has different meanings accordingly to clinicopathological features as Gleason score (GS), PSA doubling time (PSA-DT), clinical stage and surgical margins status. In addition, there is no consensus about the best PSA threshold (≥0.05, 0.2 or 0.4ng/mL) to define BCR until this moment.[4–7] Several prognostic markers, such as GS, clinical stage, and pretreatment prostate-specific antigen (PSA) levels,
have been reported, but they have limited prognostic value for individual patients. Therefore, it is necessary to find other effective biomarkers to predict the BCR of prostate cancer.

Some genes, such as ras association domain-containing protein 1 (RASSF1A), adenomatous polyposis coli (APC) and encode glutathione S-transferase pi 1 (GSTP1) have been shown to be hypermethylated in prostate cancer but not in normal tissue, further improving the diagnostic sensitivity of prostate cancer. Epigenetic mechanisms such as DNA methylation were also found to be involved in the regulation of metastasis development. Therefore, it is reasonable to believe that the hypermethylation of certain genes may predict the biological behavior of tumors and may serve as an effective biomarker of tumor progression. Paired-like homeodomain transcription factor 2 (PITX2) is a bicoid-related transcription factor induced by the Wnt/Dvl/β-catenin pathway and is required for cell type-specific proliferation. Several studies have shown that hypermethylation of PITX2 is closely related to BCR in patients with prostate cancer after radical prostatectomy. However, largely owing to the relatively small sample sizes of the individual studies, the prognostic role of PITX2 methylation in prostate cancer and the patients most likely to be recommended for PITX2 methylation tests to assess individual risk remain controversial. Therefore, we performed this systematic meta-analysis by combining data from published research to evaluate the association of PITX2 methylation with BCR in prostate cancer patients.

2. Materials and methods

2.1. Data sources

The PubMed, EMBASE and Cochrane Library databases were systematically searched for eligible studies. The search time was from database inception to April 1, 2018. A combination of free-text words and MeSH terms was used as follows: (prostate cancer/prostate neoplasms) AND (paired-like homeodomain transcription factor 2 [PITX2]) AND (methylation/hypermethylation) AND (recurrence/relapse/biochemical recurrence). Reference lists from eligible studies were also thoroughly searched for potential relevant studies.

2.2. Study selection, meta-analysis inclusion criteria, and data extraction

The identified publications were carefully screened. Two reviewers (J Q and XM) screened all publications identified based on our inclusion criteria. In the event of disagreement between the 2 reviewers, we obtained and inspected the full-text article independently. In total, 7 studies were included in the final analysis. The inclusion criteria were as follows:

(1) clinical trial or research, not letters or reviews;
(2) trials/research focusing on patients with prostate cancer;
(3) study exploring the relationship between PITX2 methylation and BCR;
(4) analysis using Cox proportional hazards modeling; and
(5) published in English.

When extracting time-to-event data, the authors attempted to use the measure reported within the text of the report. When relevant data were not reported in the text, Engauge Digitizer software (http://digitizer.sourceforge.net) was used to extract the data directly from the Kaplan–Meier survival curve reported in the article.

3. Results

3.1. Study selection and characteristics

The search strategy identified 160 records that were screened for inclusion. 37 studies were excluded on the ground of duplicate or overlapping reporting. Based on title and abstract review, a total of 20 studies were determined to be inapplicable to BCR risk of prostate cancer and were excluded. Additionally, we excluded 12 studies based on lack of sufficient data. In total, 7 studies with a total of 2185 cases were collected in the meta-analysis (Fig. 1). All the patients were diagnosed with prostate cancer following radical prostatectomy. According to GS, patients in 1 trial were considered to have high-risk prostate cancer (GS 8–10 and/or a PSA level >20 ng/mL), whereas in another 4 trials, more than 50% of the patients had intermediate-or high-risk prostate cancer (GS >7). The methods used to detect PITX2 methylation included quantitative methylation-specific PCR (qMSP) and microarray EpiChip: 4 studies used qMSP, 1 study used microarray EpiChip, and 2 studies used both qMSP and microarray EpiChip. The selected patients were from North America and Europe: 3 studies were from North America, 3 studies were from Europe, and 1 study included patients from both North America and Europe. The other general information on these studies is presented in Table 1. BCR was defined as 2 consecutive increased total PSA measurements, which was defined as total serum PSA 0.2 ng/mL or greater.

3.2. Publication bias

Begg or Egger tests revealed no evidence of publication bias across the included studies regarding BCR (Begg test, P = .488; Egger test, P = .588; Fig. 2).

3.3. Association of PITX2 methylation and biochemical recurrence

The combined analysis of the 7 studies showed that high methylation status of PITX2 was associated with BCR (HR = 2.71, 95% CI, 2.21–3.31; P < .000; the fixed effects model; Fig. 3). Because of the high proportion of high-risk patients in 1 trial the other 6 trials were included for a pooled estimate of 5-year BCR-free survival to guarantee study homogeneity. The pooled estimate of 5-year BCR-free survival of patients with high methylation status (71%; 95% CI, 59%–
Fig. 4) was significantly lower than that of patients with low methylation status (90%; 95% CI, 86%-95%; Fig. 4) (OR = 3.50; 95% CI, 2.67–4.60, \( P = .000 \), fixed effects model). A subgroup analysis was conducted according to patient region; the combined HR was 2.14 (95% CI, 1.49–3.08, \( P = .000 \)) for Europe and 3.00 (95% CI, 2.22–4.04, \( P = .000 \)) for North America (Fig. 5). Another subgroup analysis was performed with detection method; the combined HR was 2.68 (95% CI, 2.02–3.55, \( P = .000 \)) for qMSP and 3.29 (95% CI, 2.31–4.68, \( P = .000 \)) for microarray EpiChip (Fig. 5). In the subgroup analysis of GSs, cutoff values were selected based on a model fit (likelihood).

**Table 1**

| Author | Year | Country          | Sample size | Method                | Cut-off of methylation |
|--------|------|------------------|-------------|-----------------------|------------------------|
| Uhl[10] | 2017 | Germany          | 260         | qMSP                  | 6.43%***               |
| Litovkin[11] | 2014 | Belgium          | 71          | qMSP                  | 24%**                  |
| Vinarskaja[12] | 2013 | Germany          | 93          | qMSP                  | median (23.3%)         |
| Dietrich[13] | 2013 | USA              | 522         | qMSP/microarray EpiChip | median (6.43%)/CMS = 0 |
| Barbe[14] | 2010 | USA and Europe   | 476         | microarray EpiChip    | NR                     |
| Schatz[15] | 2010 | USA              | 157         | qMSP/microarray EpiChip | NR*                   |
| Weiss[16] | 2009 | USA              | 606         | qMSP                  | median (NR)            |

* Cutoff values were selected based on a model fit (likelihood).
** The cut-off maximizing this measure defined the decision point.
*** Cutoff values according to Dietrich et al. CMS = calibrated methylation score according to Schatz et al. NR = not reported.
high methylation status of PITX2 was associated with BCR, irrespective of whether GS was $<7$ (HR = 3.7, 95% CI, 1.52–9.01, $P = .004$), $=7$ (HR = 2.08, 95% CI, 1.39–3.11, $P = .000$), $>7$ (HR = 3.9, 95% CI, 1.21–12.59, $P = .023$), or $>8$ (HR = 3.15, 95% CI, 1.77–5.61, $P = .000$) (Fig. 5). In addition, for subgroups defined by tumor cell contents, pathological stage, surgical margin status and ethnicity, the HRs in the analyses of BCR favoured low methylation status in the following subgroups:

![Funnel plot](image1.png)

**Figure 2.** Deek funnel plot with 95% confidence intervals for publication bias testing.

![Forest plot](image2.png)

**Figure 3.** Meta-analysis (Forest plot) showing hazard ratios of the PITX2 methylation on BCR risk. Hazard ratios for each trial are represented by the squares, the size of the square represents the weight of the trial in the meta-analysis, and the horizontal line crossing the square represents the 95% confidence interval. The diamonds represent the estimated pooled effect using the fixed-effect model. All $P$ values are 2-sided. BCR = biochemical recurrence, PITX2 = paired-like homeodomain transcription factor 2.
patients with tumor cell content > 75%, pathological stage of pT2 (HR = 3.35, 95% CI, 1.60–6.98) or pT3 (HR = 1.82, 95% CI, 1.04–3.20), patients with (HR = 2.14, 95% CI, 1.04–3.68) or without (HR = 5.86, 95% CI, 2.70–12.68) tumor involvement of surgical margins, and patients who were white (HR = 3.46, 95% CI, 1.86–6.44) or black (HR = 5.29, 95% CI, 1.72–16.24).

4. Discussion

According to the latest statistics in 2016, prostate cancer has become the most common incident cancer for men (1.4 million cases). Due to high heterogeneity in the clinical course of prostate cancer, it is essential to determine the best methods to monitor disease progression through prognostic biomarkers, risk stratify individual patients and implement personalized treatment strategies. Aberrant DNA hypermethylation is considered an early landmark event in carcinogenesis. Hypermethylation of certain genes, such as APC, ABHD9, and Chr3-EST, has been reported to affect the biochemical recurrence of prostate cancer.

The human PITX2 gene encoded protein has been proved to be a transcription factor that regulates the expression of procollagen lysyl hydroxylase. It is reported that PITX2 hypermethylation is closely related to the prognosis of several tumor types, including acute myeloid leukemia, lung cancer, and breast cancer. Here, we focused on PITX2 methylation in prostate cancer and collected complete articles to infer potential prognostic value. Patients with high methylation status of PITX2 were more likely to experience BCR and to associated have a lower 5-year BCR-free survival, suggesting that PITX2 hypermethylation is an effective predictor of prostate cancer progression. Another study has confirmed PITX2 hypermethylation leads to PITX2 silencing and patients with decreased PITX2 mRNA level experienced significantly earlier BCR. Notably, it revealed an excellent correlation between PITX2 methylation and ERG overexpression, a common oncogenic ETS family transcription factor acting to promote prostate cancer invasion and progression. Then, we conducted subgroup analyses defined by patient region, detection method, GS, tumor cell content, pathological stage, surgical margin status and ethnicity. In the subgroup analysis according to GS, PITX2 methylation status was also shown to be a prognostic marker to predict BCR in patients, irrespective of low, intermediate or high risk. In recent years, a new and reliable diagnostic microarray, EpiChip, for detecting the methylation status of PITX2 has been developed to improve the ability to predict the prognosis of prostate cancer after radical prostatectomy.
of the HR to quantify the prognostic value of PITX2 methylation detected by qMSP or microarray EpiChip were highly similar and significantly larger than 1, suggesting that qMSP was as sensitive as microarray EpiChip at detecting PITX2 methylation in patients with prostate cancer. The application of microarray technology requires a validated diagnostic platform, the Affymetrix GeneChip System (Affymetrix, Santa Clara, CA). Since the platform is not regular laboratory equipment, the utility of the microarray test is limited. In addition, microarray-based detection methods can be applied to only complete formalin-fixed, paraffin-embedded sections, not to other biopsy samples. Based on DNA quantitative technology, qMSP is capable of analyzing a variety of biological samples, even samples that contain only minute amounts of DNA. With simple technical procedures and highly concordant results with microarray EpiChip, qMSP may be more recommended for use in clinical applications. Patients with positive tumor margins following radical prostatectomy are reported to be more likely to develop

| Study ID | Region/European | Uhl (2017) | 1.77 (1.01, 3.10) | 6.31 | Uhl (2017) | 1.77 (1.01, 3.10) | 6.31 |
|----------|----------------|------------|------------------|------|------------|------------------|------|
|          | Litovkin (2014) | 3.25 (1.61, 6.57) | 4.01 | Litovkin (2014) | 3.25 (1.61, 6.57) | 4.01 |
|          | Vinarskaia (2013) | 1.94 (1.01, 3.73) | 4.65 | Vinarskaia (2013) | 1.94 (1.01, 3.73) | 4.65 |
|          | Subtotal (I-squared = 0.0%, p = 0.390) | 2.14 (1.49, 3.08) | 14.96 | Subtotal (I-squared = 0.0%, p = 0.390) | 2.14 (1.49, 3.08) | 14.96 |
|          | Region-North America | Dietrich (2013) | 2.61 (1.80, 3.81) | 14.11 | Dietrich (2013) | 2.61 (1.80, 3.81) | 14.11 |
|          | Schatz (2010) | 5.40 (2.00, 14.50) | 2.02 | Schatz (2010) | 5.40 (2.00, 14.50) | 2.02 |
|          | Weiss (2009) | 3.40 (1.90, 6.00) | 6.00 | Weiss (2009) | 3.40 (1.90, 6.00) | 6.00 |
|          | Subtotal (I-squared = 3.1%, p = 0.356) | 3.00 (2.22, 4.04) | 22.13 | Subtotal (I-squared = 3.1%, p = 0.356) | 3.00 (2.22, 4.04) | 22.13 |
|          | Method-qMSP | Uhl (2017) | 1.77 (1.01, 3.10) | 6.31 | Uhl (2017) | 1.77 (1.01, 3.10) | 6.31 |
|          | Litovkin (2014) | 3.25 (1.61, 6.57) | 4.01 | Litovkin (2014) | 3.25 (1.61, 6.57) | 4.01 |
|          | Vinarskaia (2013) | 1.94 (1.01, 3.73) | 4.65 | Vinarskaia (2013) | 1.94 (1.01, 3.73) | 4.65 |
|          | Subtotal (I-squared = 18.9%, p = 0.290) | 3.40 (1.90, 6.00) | 6.00 | Subtotal (I-squared = 18.9%, p = 0.290) | 3.40 (1.90, 6.00) | 6.00 |
|          | Method-qMSP | Dietrich (2013) | 4.12 (1.49, 11.40) | 1.92 | Dietrich (2013) | 4.12 (1.49, 11.40) | 1.92 |
|          | Banez (2010) | 4.00 (1.70, 12.00) | 2.01 | Banez (2010) | 4.00 (1.70, 12.00) | 2.01 |
|          | Schatz (2010) | 3.29 (2.31, 4.68) | 15.99 | Schatz (2010) | 3.29 (2.31, 4.68) | 15.99 |
|          | Weiss (2009) | 3.40 (1.90, 6.00) | 6.00 | Weiss (2009) | 3.40 (1.90, 6.00) | 6.00 |
|          | Subtotal (I-squared = 0.0%, p = 0.662) | 3.40 (1.90, 6.00) | 6.00 | Subtotal (I-squared = 0.0%, p = 0.662) | 3.40 (1.90, 6.00) | 6.00 |
|          | Method-qMSP | Dietrich (2013) | 2.00 (1.20, 3.30) | 7.75 | Dietrich (2013) | 2.00 (1.20, 3.30) | 7.75 |
|          | Banez (2010) | 2.00 (1.20, 3.30) | 7.75 | Banez (2010) | 2.00 (1.20, 3.30) | 7.75 |
|          | Weiss (2009) | 3.40 (1.90, 6.00) | 6.00 | Weiss (2009) | 3.40 (1.90, 6.00) | 6.00 |
|          | Subtotal (I-squared = 0.0%, p = 0.808) | 2.00 (1.20, 3.30) | 7.75 | Subtotal (I-squared = 0.0%, p = 0.808) | 2.00 (1.20, 3.30) | 7.75 |
|          | Method-qMSP | Dietrich (2013) | 3.90 (1.20, 12.50) | 1.44 | Dietrich (2013) | 3.90 (1.20, 12.50) | 1.44 |
|          | Banez (2010) | 3.90 (1.20, 12.50) | 1.44 | Banez (2010) | 3.90 (1.20, 12.50) | 1.44 |
|          | Weiss (2009) | 4.00 (1.61, 6.57) | 4.01 | Weiss (2009) | 4.00 (1.61, 6.57) | 4.01 |
|          | Subtotal (I-squared = 0.0%, p = 0.678) | 3.90 (1.20, 12.50) | 1.44 | Subtotal (I-squared = 0.0%, p = 0.678) | 3.90 (1.20, 12.50) | 1.44 |
|          | Heterogeneity between groups: p = 0.545 | 2.72 (2.37, 3.14) | 100.00 | Overall (I-squared = 0.0%, p = 0.655) | 2.72 (2.37, 3.14) | 100.00 |

Figure 5. Meta-analysis (Forest plot) showing hazard ratios of the PITX2 methylation on BCR risk. Subgroup analysis of region: European/North America; Method: qMSP/microarray EpiChip; and Gleason score <7/7/> = 7. Hazard ratios for each trial are represented by the squares, the size of the square represents the weight of the trial in the meta-analysis, and the horizontal line crossing the square represents the 95% confidence interval. The diamonds represent the estimated pooled effect using the fixed-effect model. All P values are 2-sided. BCR= biochemical recurrence, PITX2 = paired-like homeodomain transcription factor 2, qMSP=quantitative methylation-specific PCR.
biological, local and systemic progression. About 50% of these patients experience recurrence; so it is an urgent need to explore predictive biomarkers in this subgroup. In the subgroup analysis defined by surgical margin status, PITX2 methylation status was also shown to be a robust predictor for BCR risk in patients with tumor involvement of surgical margins, and this finding may help develop a risk-adjusted approach to adjuvant therapy after radical prostatectomy for those patients.

In future studies, it is necessary to confirm the clinical significance of PITX2 methylation in a suited patient cohort (such as an adjuvant therapy cohort).

This study had several limitations. First, we excluded studies that lacked survival data (e.g., HR, CI or survival curves). Second, our endpoint was BCR. Although early BCR is closely related to the risk of disease metastasis and cancer-related death, more studies in the future are needed to assess the prognostic value of PITX2 methylation regarding these clinical end points. Last, some statistical results have heterogeneity, which may be derived from the differences in the patient clinical characteristics, detection methods, cut-off values or any other technical issues.

In conclusion, PITX2 hypermethylation status is an effective molecular predictor of BCR risk in patients with prostate cancer after radical prostatectomy. Adding PITX2 methylation status measurements to routine prostate cancer management may help assess individual prognostic risk and define patients who may benefit from further therapeutic intervention. Larger-scale and more standard investigations are required to better understand the role of PITX2 methylation in disease progression (e.g., metastasis and overall survival) and its utility in clinical applications (involving different therapeutic modalities).

Author contributions
Qi Jiang and Mixue Xie: conception and design of the study, protocol development, searching for studies, acquisition, analysis and interpretation of data, drafting the article; Mengye He, Feifei Yan, Ming Chen and Suzhen Xu: searching for studies, acquisition, analysis and interpretation of data; Xiaochen Zhang and Peng Shen: conception and design of the study, protocol development, revision of the article.

Data curation: Qi Jiang, Mixue Xie, Mengye He, Feifei Yan, Ming Chen, Suzhen Xu.

Formal analysis: Qi Jiang, Mixue Xie, Mengye He, Feifei Yan.

Funding acquisition: Mixue Xie, Xiaochen Zhang.

Project administration: Xiaochen Zhang.

Resources: Qi Jiang, Ming Chen, Suzhen Xu.

Software: Suzhen Xu.

Supervision: Peng Shen.

Writing – original draft: Qi Jiang, Mixue Xie.

Writing – review & editing: Xiaochen Zhang, Peng Shen.

References
[1] Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859–64.
[2] Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910–4.
[3] Taplin ME. Biochemical (prostate-specific antigen) relapse: an oncologist's perspective. Rev Urol 2003;5(suppl 2):S3–13.
[4] Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:840–5.
[5] Hedenreich A, Bastian PJ, Bellmunt J, et al. European association of urology. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–79.
[6] Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973–8.
[7] Mir MC, Li J, Klink JC, et al. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol 2014;66:204–10.
[8] Montironi R, Santoni M, Mazzucchelli R, et al. Prostate cancer: from Gleason scoring to prognostic grade grouping. Expert Rev Anticancer Ther 2016;16:433–40.
[9] Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2015;21:4097–106.
[10] Yoon HY, Kim SK, Kim YW, et al. Combined hypermethylation of APC and GSY1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis. J Biomed Screen 2012;17:987–92.
[11] Phe V, Cussenot O, Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010;105:1164–70.
[12] Li Q, Chen H. Epigenetic modifications of metastasis suppressor genes in colon cancer metastasis. Epigenetics 2011;6:849–52.
[13] Wang Y, Shang Y. Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res 2013;319:160–9.
[14] Kiousis C, Briata P, Baek SH, et al. Identification of a Wnt/β-catenin–Pitx2 pathway mediating cell-type-specific proliferation during development. Cell 2002;111:673–85.
[15] Uhl B, Gevensleben H, Tolkach Y, et al. PITX2 DNA methylation as biomarker for individualized risk assessment of prostate cancer in core biopsies. J Mol Diagn 2017;19:107–14.
[16] Litovkin K, Joniau S, Lerut E, et al. Methylaton of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol 2014:140:1849–61.
[17] Vinarskaja A, Schulz WA, Ingenwerth M, et al. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Urol Oncol 2013;31:622–7.
[18] Dietrich D, Hasinger O, Baizez LL, et al. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn 2013;15:270–9.
[19] Baizez LL, Sun L, van Leenders GJ, et al. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol 2010;184:149–56.
[20] Schatz P, Dietrich D, Koenig T, et al. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation. J Mol Diagn 2010;12:345–53.
[21] Weiss G, Cottrell S, Distler J, et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009;181:1678–85.
[22] Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882–93.
[23] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;31:629–34.
[24] Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018;4:1353–68.
[25] Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development. Br J Cancer 2009;100:240–5.
[26] Alumkal JJ, Zhang Z, Humphreys EB, et al. Effect of DNA methylation on identification of aggressive prostate cancer. Urology 2008;72:1234–9.
[27] Ellinger J, Bastian PJ, Jurgan T, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008;71:161–7.
[28] Henrique R, Ribeiro FR, Fonseca D, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007;13:6122–9.
[29] Cottrell S, Jung K, Kristiansen G, et al. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 2007;177:1753–8.
[30] Toyota M, Kopecky KJ, Toyota MO, et al. Methylation profiling in acute myeloid leukemia. Blood 2001;97:2823–9.
[31] Anglim PP, Galler JS, Koss MN, et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer 2008;7:62.
[32] Harbeck N, Nimmrich I, Hartmann A, et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 2008;26:5036–42.
[33] Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347–51.
[34] Touijer K, Kuroiwa K, Vickers A, et al. Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy. Eur Urol 2006;49:853–8.
[35] Fradet V, Lessard L, Bégin LR, et al. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004;10:8460–4.